Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 13/20 | 0.39 |
| ▸ | HTR2C | P28335 | 4/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | GPR183 | P32249 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2768974 | 0.97 | HTR2A (0.38) | HTR2AHTR2CKCNH2ABCB11CYP1A2 | |
| SCHEMBL342239 | 0.93 | P2RX3 (0.37) | HTR2AKCNH2CACNA1GDRD4KDM4E | |
| SCHEMBL341173 | 0.90 | MMP1 (0.39) | HTR2AKCNH2DRD1SLC6A2DRD3 | |
| SCHEMBL340943 | 0.89 | HSD11B1 (0.37) | KCNH2CYP2C19FFAR1POLB | |
| SCHEMBL341805 | 0.88 | HTR2A (0.45) | HTR2AHTR2CKCNH2ABCB11CYP1A2 | |
| SCHEMBL2768143 | 0.88 | HTR2A (0.45) | HTR2AHTR2CKCNH2ABCB11CYP1A2 | |
| SCHEMBL2769257 | 0.88 | HTR2A (0.45) | HTR2AHTR2CKCNH2ABCB11CYP1A2 | |
| SCHEMBL341011 | 0.88 | ALDH1A1 (0.40) | HTR2AHTR2CKCNH2ABCB11CYP1A2 | |
| SCHEMBL340821 | 0.88 | SIGMAR1 (0.40) | FFAR1 | |
| SCHEMBL340243 | 0.88 | HTR2A (0.40) | HTR2AHTR2CKCNH2ABCB11CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2983473-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS Mountain Llc (US) | 2016-02-17 | — | — | EP | claimed |
| US-20140350064-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC | 2014-11-27 | — | — | US | claimed |
| WO-2014144130-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC (US) | 2014-09-18 | — | — | WO | claimed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | claimed |
| EP-1461339-B1 | SPIROAZACYCLIC COMPOUNDS AS MONOAMINE RECEPTOR MODULATORS | ACADIA PHARM INC (US) | 2010-04-28 | — | — | EP | claimed |
| US-20090131418-A1 | SPIROAZACYCLIC COMPOUNDS AS MONOAMINE RECEPTOR MODULATORS | ACADIA PHARAMCEUTICALS, INC. (US) | 2009-05-21 | — | — | US | claimed |
| US-7402590-B2 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. (US) | 2008-07-22 | — | — | US | claimed |
| US-20070161621-A1 | SPIROAZACYCLIC COMPOUNDS AS MONOAMINE RECEPTOR MODULATORS | ACADIA PHARMACEUTICALS (US) | 2007-07-12 | — | — | US | claimed |
| US-6911452-B2 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. (US) | 2005-06-28 | — | — | US | claimed |
| US-20030166928-A1 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. | 2003-09-04 | — | — | US | claimed |
| EP-2983473-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS Mountain Llc (US) | 2016-02-17 | — | — | EP | disclosed |
| US-20140350064-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC | 2014-11-27 | — | — | US | disclosed |
| WO-2014144130-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120122874-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR TREATING DEPRESSION | Sunovion Inc. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20060199794-A1 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. | 2006-09-07 | — | — | US | disclosed |
| US-20050256108-A1 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. | 2005-11-17 | — | — | US | disclosed |
| US-20050176680-A1 | Eszopiclone stimulates GABA receptors, and serotonin reuptake inhibitor (citalopram), norepinephrine reuptake inhibitor (desipramine), 5-HT2A modulator, or dopamine reuptake inhibitor (amineptine) | SEPRACOR, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| US-6911452-B2 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. (US) | 2005-06-28 | — | — | US | disclosed |
| US-20030166928-A1 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256108-A1 | Spiroazacyclic compounds as monoamine receptor modulators | MAOA, MAOB, HTR5A | HTR2A 4/4885HTR2C 13/4885KCNH2 1196/4885 |
| US-20050176680-A1 | Eszopiclone stimulates GABA receptors, and serotonin reuptake inhibitor (citalopram), norepinephrine reuptake inhibitor (desipramine), 5-HT2A modulator, or dopamine reuptake inhibitor (amineptine) | HTR2A, HTR2C, HTR5A | HTR2A 1/4885HTR2C 2/4885KCNH2 1475/4885 |
| US-20090131418-A1 | SPIROAZACYCLIC COMPOUNDS AS MONOAMINE RECEPTOR MODULATORS | MAOA, MAOB, HTR5A | HTR2A 4/4885HTR2C 13/4885KCNH2 1196/4885 |
| US-20030166928-A1 | Spiroazacyclic compounds as monoamine receptor modulators | MAOA, MAOB, HTR5A | HTR2A 4/4885HTR2C 13/4885KCNH2 1196/4885 |
| US-20120122874-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR TREATING DEPRESSION | HTR2A, HTR5A, HTR2C | HTR2A 1/4885HTR2C 3/4885KCNH2 678/4885 |
| US-20070161621-A1 | SPIROAZACYCLIC COMPOUNDS AS MONOAMINE RECEPTOR MODULATORS | MAOA, MAOB, HTR5A | HTR2A 4/4885HTR2C 13/4885KCNH2 1196/4885 |
| US-20060199794-A1 | Spiroazacyclic compounds as monoamine receptor modulators | MAOA, MAOB, HTR5A | HTR2A 4/4885HTR2C 13/4885KCNH2 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.